Jacobi Capital Management LLC Sells 1,619 Shares of Johnson & Johnson (NYSE:JNJ)

Jacobi Capital Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 4.4% during the fourth quarter, Holdings Channel reports. The firm owned 35,157 shares of the company’s stock after selling 1,619 shares during the period. Jacobi Capital Management LLC’s holdings in Johnson & Johnson were worth $5,084,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of JNJ. Janus Henderson Group PLC lifted its holdings in Johnson & Johnson by 228.1% during the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock worth $549,223,000 after acquiring an additional 2,356,359 shares during the period. Franklin Resources Inc. lifted its holdings in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after acquiring an additional 1,729,281 shares during the period. Holocene Advisors LP bought a new stake in Johnson & Johnson during the third quarter worth $225,040,000. FMR LLC lifted its holdings in Johnson & Johnson by 7.4% during the third quarter. FMR LLC now owns 18,316,920 shares of the company’s stock worth $2,968,440,000 after acquiring an additional 1,265,748 shares during the period. Finally, Proficio Capital Partners LLC lifted its holdings in Johnson & Johnson by 7,516.1% during the fourth quarter. Proficio Capital Partners LLC now owns 1,245,771 shares of the company’s stock worth $180,163,000 after acquiring an additional 1,229,414 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $167.08 on Tuesday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The business has a 50-day simple moving average of $151.33 and a 200 day simple moving average of $156.08. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market cap of $402.26 billion, a price-to-earnings ratio of 25.12, a PEG ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the business earned $2.29 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JNJ. Raymond James dropped their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Guggenheim boosted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.